BSX - Boston Scientific Corporation

NYSE - Nasdaq Real-time price. Currency in USD
32.925
+0.775 (+2.41%)
As of 12:55PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close32.150
Open32.330
Bid32.920 x 1200
Ask32.930 x 4000
Day's range32.220 - 33.030
52-week range24.540 - 37.300
Volume3,375,672
Avg. volume8,205,609
Market cap45.43B
Beta0.99
PE ratio (TTM)406.48
EPS (TTM)0.081
Earnings date25 Jul 2018 - 30 Jul 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est33.07
Trade prices are not sourced from all markets
  • Should You Buy Boston Scientific Corporation (NYSE:BSX) Now?
    Simply Wall St.3 hours ago

    Should You Buy Boston Scientific Corporation (NYSE:BSX) Now?

    Let’s talk about the popular Boston Scientific Corporation (NYSE:BSX). The company’s shares saw a significant share price rise of over 20% in the past couple of months on the NYSE.Read More...

  • Has Boston Scientific (BSX) Outpaced Other Medical Stocks This Year?
    Zacksyesterday

    Has Boston Scientific (BSX) Outpaced Other Medical Stocks This Year?

    Is Boston Scientific Corporation (BSX) Outperforming Other Medical Stocks This Year?

  • Tap Cardiovascular Devices Market Boom With These 3 Stocks
    Zacksyesterday

    Tap Cardiovascular Devices Market Boom With These 3 Stocks

    Consider these three stocks in the rapidly-growing cardiovascular devices market.

  • BSX or BAX: Which is a Better Pick for Your Portfolio Now?
    Zacks2 days ago

    BSX or BAX: Which is a Better Pick for Your Portfolio Now?

    After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).

  • Zacks.com featured highlights include: General Motors, Boston Scientific, Antero NRG, AMC and Celanese
    Zacks3 days ago

    Zacks.com featured highlights include: General Motors, Boston Scientific, Antero NRG, AMC and Celanese

    Zacks.com featured highlights include: General Motors, Boston Scientific, Antero NRG, AMC and Celanese

  • Top 5 ROE Stocks to Buy as Trump Keeps Trade War Fears Alive
    Zacks4 days ago

    Top 5 ROE Stocks to Buy as Trump Keeps Trade War Fears Alive

    ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
    Zacks4 days ago

    Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

    Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

  • Boston Scientific’s Valuations and Price Performance
    Market Realist7 days ago

    Boston Scientific’s Valuations and Price Performance

    Boston Scientific’s (BSX) enterprise value is $45.1 billion, and its enterprise-value-to-revenue ratio is 4.98x. The stock is trading at a forward PE multiple of 21.86x, which is expected to have a five-year growth multiple of 2.13x. Its price-to-sales ratio is 5.23x, and its price-to-book ratio is 6.72x. Its enterprise-value-to-EBITDA ratio is 18.5x.

  • Boston Scientific’s Cash Flow Trend: What It Indicates
    Market Realist7 days ago

    Boston Scientific’s Cash Flow Trend: What It Indicates

    In the first quarter of 2018, Boston Scientific (BSX) generated $193 million from operating activities compared to $7 million in Q1 2017. Boston Scientific used $173 million in investing activities in Q1 2018 compared to $140 million in Q1 2017. Boston Scientific generated $130 million from financing activities in Q1 2018 compared to $15 million in Q1 2017.

  • Analyzing Boston Scientific’s Financial Performance
    Market Realist7 days ago

    Analyzing Boston Scientific’s Financial Performance

    In Q1 2018, Boston Scientific (BSX) generated sales of $2.4 billion compared to $2.2 billion in Q1 2017. The company’s cost of goods sold increased from $650 million in Q1 2017 to $672 million in Q1 2018. The increase was due to the positive impact of cost reductions from Boston Scientific’s process improvement programs and restructuring programs.

  • Boston Scientific’s Cardiovascular Segment: Q1 2018 Performance
    Market Realist8 days ago

    Boston Scientific’s Cardiovascular Segment: Q1 2018 Performance

    Boston Scientific’s (BSX) Cardiovascular segment is comprised of cardiology and peripheral interventions. Its operating income was $290 million, or 31.1% of the segment’s revenues, in Q1 2018, up from $233 million, or 27.3% of the segment’s revenues, in Q1 2017. Worldwide interventional cardiology sales increased 10%, from $590 million in Q1 2017 to $645 million in Q1 2018.

  • Boston Scientific’s Rhythm Management & Neuro Segment
    Market Realist8 days ago

    Boston Scientific’s Rhythm Management & Neuro Segment

    Revenues from Boston Scientific’s (BSX) urology and pelvic health area increased from $262 million in Q1 2017 to $293 million in Q1 2018. Its US revenues increased from $183 million in Q1 2017 to $197 million in Q1 2018.

  • Boston Scientific’s Electrophysiology and Neuromodulation Areas
    Market Realist8 days ago

    Boston Scientific’s Electrophysiology and Neuromodulation Areas

    Worldwide revenues of Boston Scientific’s (BSX) electrophysiology business, which includes less invasive medical technologies for rate and rhythm disorders of the heart, grew 20% from $64 million in Q1 2017 to $75 million in Q1 2018. Electrophysiology revenues from the United States increased from $32 million in Q17 to $35 million in 1Q18.

  • Boston Scientific’s Investment in Millipede
    Market Realist8 days ago

    Boston Scientific’s Investment in Millipede

    In January, Boston Scientific (BSX) closed an investment in Millipede and entered into an acquisition option agreement with the company. Millipede is a private company that has developed the IRIS annuloplasty ring system targeted for treating mitral regurgitation.

  • Analyst Recommendations for Boston Scientific and Peers in June
    Market Realist8 days ago

    Analyst Recommendations for Boston Scientific and Peers in June

    Of the 24 analysts covering Boston Scientific in June, 19 of them have given the stock a “buy” or higher rating. Five of them have given it a “hold.” The mean rating for the stock is 1.67 with a target price of $32.76. In June, 16 of the 20 analysts covering Abbott Laboratories (ABT) gave the stock a “buy” or higher rating.

  • Boston Scientific’s Recent Acquisitions and What They Mean
    Market Realist8 days ago

    Boston Scientific’s Recent Acquisitions and What They Mean

    In April, Boston Scientific (BSX) closed two acquisitions: NxThera and nVision Medical. The NxThera closing was on April 30. NxThera developed the Rezūm System, which is a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (or BPH). Boston Scientific already had a minority stake in NxThera.

  • The Wall Street Journal9 days ago

    [$$] Stryker Says It’s Not in Deal Talks With Boston Scientific

    Medical-technology company Stryker Corp. said Wednesday it is not in discussions with Boston Scientific Corp. regarding a potential takeover. On Monday, The Wall Street Journal reported Stryker had made a takeover approach to Boston Scientific, a move that would create a medical-device giant and would be the latest effort to consolidate a corner of the health-care industry that has produced a raft of large deals lately. Stryker said in a filing with the Securities and Exchange Commission on Wednesday it doesn’t typically comment on these matters, but it chose to respond following market speculation about a possible deal for Boston Scientific.

  • Market Realist9 days ago

    Stryker Declines Buyout Talks with Boston Scientific

    On June 13, Stryker (SYK) said in a regulatory filing that it’s not in discussions with Boston Scientific (BSX) related to its acquisition. The company released the statement following rumors of a potential acquisition offer made by Stryker to Boston Scientific on June 11, as we reported in Boston Scientific Surges on Rumors of Takeover Bid from Stryker.

  • Why J.C. Penney, KB Home, and Boston Scientific Slumped Today
    Motley Fool9 days ago

    Why J.C. Penney, KB Home, and Boston Scientific Slumped Today

    Find out which of these companies might not get the acquisition news it had hoped for.

  • Stryker Says It's Not Planning To Acquire Boston Scientific
    Investor's Business Daily9 days ago

    Stryker Says It's Not Planning To Acquire Boston Scientific

    Medtech player Stryker isn't in discussions to acquire Boston Scientific, Stryker said Wednesday — prodding shares to pop as Boston Scientific stock toppled more than 6%.

  • Add These 7 GARP Stocks to Your Kitty for Maximum Returns
    Zacks9 days ago

    Add These 7 GARP Stocks to Your Kitty for Maximum Returns

    Growth at a reasonable price or the GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

  • Reuters9 days ago

    Medical device maker Stryker says not in talks to buy Boston Scientific

    Stryker's shares rose 7 percent to $174 in premarket trading after falling 9 percent in the last two days. Boston Scientific's shares fell 6.8 percent to $31.60. A potential deal between Stryker and Boston Scientific would create a combined company with a market value of more than $110 billion.

  • 3 Medical Instrument Stocks to Gain on Solid Market Prospects
    Zacks9 days ago

    3 Medical Instrument Stocks to Gain on Solid Market Prospects

    Here we take a peek at three Medical Instrument stocks that are likely to deliver strong returns in the days to come.

  • MarketWatch9 days ago

    Stryker's stock surges after disclosing it's not discussing potential buyout of Boston Scientific

    Shares of Boston Scientific Corp. tumbled 6.4%, and Stryker Corp.'s stock shot up 6.4%, after Stryker said it was not in talks to buy Boston Scientific, dispelling speculation after The Wall Street Journal reported on Monday that Boston Scientific had been approached by Stryker. In a filing with the Securities and Exchange Commission, Stryker said in a statement: "While it is Stryker Corporation's (Stryker) longstanding practice not to comment on these matters, today Stryker issued the following statement in response to the market speculation about a proposal to acquire Boston Scientific Corporation: 'Stryker is not in discussions with Boston Scientific Corporation regarding a potential acquisition.'" The medical technology products company's stock had plunged 9.2% in two days since the WSJ report, while Boston Scientific shares had rallied 5.9% and the S&P 500 had inched up 0.3%.

  • Stryker Says It's Not in Merger Talks With Boston Scientific
    Bloomberg9 days ago

    Stryker Says It's Not in Merger Talks With Boston Scientific

    Stryker Corp. said it isn’t in talks with medical-device giant Boston Scientific Corp. about a potential acquisition, responding to a report that it had sought a deal. The Wall Street Journal reported two days ago that Stryker had approached Boston Scientific about a potential merger, sending the target company’s shares soaring. “Stryker is not in discussions with Boston Scientific Corporation regarding a potential acquisition,” the Kalamazoo, Michigan-based company said in a regulatory filing Wednesday.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes